UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No.__)*
Orphan Medical Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
--------------------------------------------------------------------------------
(Title of Class of Securities)
687303107
--------------------------------------------------------------------------------
(CUSIP Number)
OrbiMed Advisors LLC
--------------------------------------------------------------------------------
OrbiMed Capital LLC
Samuel D. Isaly
767 Third Avenue
New York, NY 10017
Telephone: (212) 739-6400
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
Copy to:
Paul S. Schreiber, Esq.
Shearman & Sterling LLP
599 Lexington Avenue
New York, New York 10022
Telephone: (212) 848-4000
April 18, 2005
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g)
check the following box |X|.
Note: Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See ss. 240.13d-7(b)
for other parties to whom copies are to be sent.
Page 1 of 15
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 (the "Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
Page 2 of 15
SCHEDULE 13D
-------------------------------- -----------------------
CUSIP No. 687303107 Page 3 of 15 Pages
-------------------------------- -----------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
OrbiMed Advisors LLC
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) |_|
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 1,080,000
EACH -------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON
WITH 0
-------------------------------------------------
10 SHARED DISPOSITIVE POWER
1,080,000
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,080,000
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES (See Instructions) |_|
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.45%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
IA
--------------------------------------------------------------------------------
Page 3 of 15
SCHEDULE 13D
-------------------------------- -----------------------
CUSIP No. 687303107 Page 4 of 15 Pages
-------------------------------- -----------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
OrbiMed Capital LLC
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) |_|
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 537,302
EACH -------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON
WITH 0
-------------------------------------------------
10 SHARED DISPOSITIVE POWER
537,302
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
537,302
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES (See Instructions) |_|
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.71%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
IA
--------------------------------------------------------------------------------
Page 4 of 15
SCHEDULE 13D
-------------------------------- -----------------------
CUSIP No. 687303107 Page 5 of 15 Pages
-------------------------------- -----------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Samuel D. Isaly
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
AF
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) |_|
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
0
NUMBER OF -------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 1,617,302
EACH -------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON
WITH 0
-------------------------------------------------
10 SHARED DISPOSITIVE POWER
1,617,302
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,617,302
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES (See Instructions) |_|
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
14.16%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
HC
--------------------------------------------------------------------------------
Page 5 of 15
Item 1. Security and Issuer.
The class of equity securities to which this Statement on Schedule 13D
relates is the Common Stock (the "Shares") of Orphan Medical Inc. (the
"Issuer"), a Delaware corporation with its principal executive offices located
at 13911 Ridgedale Drive, Suite 475, Minnetonka, MN 55305.
Item 2. Identity and Background.
(a) This Statement is being filed by OrbiMed Advisors LLC, a limited
liability company organized under the laws of Delaware, OrbiMed Capital LLC, a
limited liability company organized under the laws of Delaware, and Samuel D.
Isaly ("Isaly"), an individual (collectively, the "Reporting Persons").
(b) - (c) OrbiMed Advisors LLC is a registered investment adviser under
the Investment Advisers Act of 1940, as amended, that acts as investment adviser
or general partner to certain clients which hold Shares of the Issuer, as more
particularly described in Item 3 below. OrbiMed Advisors LLC has its principal
offices at 767 Third Avenue, 30th Floor, New York, New York 10017.
OrbiMed Capital LLC is a registered investment adviser under the
Investment Advisers Act of 1940, as amended, that acts as general partner to
certain limited partnerships as more particularly described in Item 3 below.
OrbiMed Capital LLC has its principal offices at 767 Third Avenue, 30th Floor,
New York, New York 10017.
Isaly, a natural person, owns a controlling interest in OrbiMed
Advisors LLC and OrbiMed Capital LLC.
The directors and executive officers of OrbiMed Advisors LLC and
OrbiMed Capital LLC are set forth on Schedules I and II, attached hereto.
Schedules I and II set forth the following information with respect to each such
person:
(i) name;
(ii) business address (or residence address where indicated);
(iii) present principal occupation or employment and the name,
principal business and address of any corporation or other
organization in which such employment is conducted; and
(iv) citizenship.
(d) - (e) During the last five years, neither the Reporting Persons nor
any Person named in Schedules I and II have been (i) convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors) or (ii) a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating
Page 6 of 15
activities subject to, federal or state securities laws or finding any violation
with respect to such laws.
(f) Isaly is a citizen of the United States.
Item 3. Source and Amount of Funds or Other Considerations.
On and prior to December 31, 2004, pursuant to the discretionary
investment management authority of OrbiMed Advisors LLC and OrbiMed Capital LLC
under their respective investment advisory contracts and limited partnership
agreements with or relating to Caduceus Capital Master Fund Ltd., Caduceus
Capital II, LP, UBS Eucalyptus Fund, LLC, and PaineWebber Eucalyptus Fund, LLC
caused these clients to purchase 1,617,302 Shares of the Issuer. The authority
referenced in the preceding sentence included authority to vote, purchase and/or
sell securities held by or on behalf of such clients, including those Shares of
the Issuer referenced in that sentence.
Following the above transactions, Isaly, as the owner of a controlling
interest in OrbiMed Advisors LLC and OrbiMed Capital LLC, is the beneficial
owner of approximately 14.16% of the outstanding Shares of the Issuer. OrbiMed
Advisors LLC is the beneficial owner of approximately 9.45% of the outstanding
Shares of the Issuer and OrbiMed Capital LLC is the beneficial owner of
approximately 4.71% of the outstanding Shares of the Issuer.
None of the Reporting Persons have acquired or disposed of any
additional Shares of the Issuer since December 31, 2004.
Item 4. Purpose of Transaction.
As described more fully in Item 3 above, this statement relates to the
acquisition of Shares by the Reporting Persons. The Shares acquired by the
Reporting Persons were acquired for the purpose of making an investment in the
Issuer and not with the intention of acquiring control of the Issuer's business
on behalf of Caduceus Capital Master Fund Ltd., Caduceus Capital II, LP, UBS
Eucalyptus Fund, LLC, PaineWebber Eucalyptus Fund, LLC or any other of the
Reporting Persons' respective advisory clients.
The Reporting Persons were previously granted and exercised the right
to appoint an observer to the Board of Directors (the "Board") of the Issuer, so
as to permit active monitoring of the operations of the Issuer. Michael B.
Sheffery, Ph.D. currently serves as the Reporting Persons' observer to the
Board.
The Reporting Persons from time to time intend to review their
investment in the Issuer on the basis of various factors, including the Issuer's
business, financial condition, results of operations and prospects, general
economic and industry conditions, the securities markets in general and those
for the Issuer's Shares in particular, as well as other developments and other
investment opportunities. Based upon such review, the Reporting Persons will
take such actions in the future as the Reporting Persons may deem appropriate in
light of the circumstances existing from time to time. Subject to the Merger
Agreement described in the next paragraph, if the Reporting Persons believe that
further investment in the Issuer is attractive, whether because
Page 7 of 15
of the market price of the Issuer's Shares or otherwise, they may acquire shares
of common stock or other securities of the Issuer either in the open market or
in privately negotiated transactions. Similarly and also subject to the Merger
Agreement described in the next paragraph, depending on market and other
factors, the Reporting Persons may determine to dispose of some or all of the
Shares currently owned by the Reporting Persons or otherwise acquired by the
Reporting Persons either in the open market or in privately negotiated
transactions.
The Issuer, Jazz Pharmaceuticals, Inc., a Delaware corporation
("Buyer"), and Twist Merger Sub, Inc., a Delaware corporation ("Sub") entered
into a Merger Agreement as of April 18, 2005 (the "Merger Agreement", attached
hereto as Exhibit B and incorporated by reference herein), which provides for,
upon the terms and subject to the conditions set forth therein, the merger of
Sub with and into the Issuer (as set forth in the Merger Agreement) in exchange
for a cash payment for all of the issued and outstanding shares of capital stock
of the Issuer (the "Merger").
Approval of the Merger Agreement by (i) the holders of a majority of
the issued and outstanding shares of the Issuer's Common Stock, $0.01 par value
per share, voting together with the holders of the Issuer's Senior Convertible
Preferred Stock, $0.01 par value per share ("Senior Preferred Stock"), voting on
an as converted basis and (ii) the holders of a majority of the issued and
outstanding shares of Senior Preferred Stock, voting as a separate class, among
other things, is required in order to consummate the transactions contemplated
by the Merger Agreement.
In connection with the execution of the Merger Agreement, Buyer has
required each stockholder of the Issuer, including OrbiMed Advisors LLC, to
enter into the Voting Agreement, dated as of April 18, 2005, among the Issuer,
Buyer, Sub, OrbiMed Advisors LLC and each stockholder of the Company signatory
thereto (the "Voting Agreement", attached hereto as Exhibit C and incorporated
by reference herein).
The Voting Agreement is described below (certain capitalized terms used
and not otherwise defined herein have the meanings ascribed to them in the
Merger Agreement).
Agreement to Vote. From April 18, 2005 until the termination of the
Voting Agreement (the "Term"), at every time as the Issuer convenes a meeting
of, or otherwise seeks a vote of, the Issuer's stockholders for the purpose of
approving the Merger, OrbiMed Advisors LLC agrees to vote, or cause to be voted,
to the extent not voted by Buyer as appointed by the Proxy (defined below), all
of its Subject Shares: (a) in favor of the approval and adoption of the Merger
Agreement and the approval of the Merger and the transactions contemplated by
the Merger Agreement; (b) against approval of any proposal made in opposition
to, or in competition with, the Merger and the transactions contemplated by the
Merger Agreement; and (c) against any actions (other than those actions that
relate to the Merger and the transactions contemplated by the Merger Agreement)
that are intended to, or could be reasonably expected to, impair the ability of
the Issuer to consummate the Merger or otherwise impede, interfere with, delay,
postpone, discourage or adversely affect the consummation of the Merger in
accordance with the terms of the Merger Agreement. OrbiMed Advisors LLC further
agrees not to enter into any
Page 8 of 15
agreement or understanding with any person to vote or give instructions in any
manner inconsistent with or violative of the foregoing terms.
Proxy. OrbiMed Advisors LLC constitutes and appoints Buyer as its proxy
(its "Proxy") to vote OrbiMed Advisors LLC's Subject Shares at every annual,
special, adjourned or postponed meeting of the stockholders of the Issuer called
for purposes of considering whether to approve the Merger Agreement or any of
the other transactions or matters contemplated by, or directly or indirectly
affecting, the Merger Agreement or to execute a written consent of stockholders
in lieu of any such meeting.
Transfer of Subject Shares. Except as otherwise contemplated by the
Merger Agreement, until the termination of the Voting Agreement, OrbiMed
Advisors LLC agrees that it will be the beneficial owner of all of its Subject
Shares and will hold such Subject Shares free and clear of all Liens and will
not, directly or indirectly, without the prior written consent of Buyer: (a)
offer for sale, sell, transfer, tender, pledge, encumber, assign or otherwise in
any way dispose of, or enter into any contract, option or other agreement (oral
or written) with respect to or consent to the offer for sale, sell, transfer,
tender, pledge, encumbrance, assignment or any other disposition of, any or all
of such Stockholder's Subject Shares, or any interest therein; (b) grant any
proxies or powers of attorney, deposit any of the Subject Shares into a voting
trust or enter into a voting agreement with respect to any of the Subject
Shares; (c) take any action that would reasonably be expected to have the effect
of preventing or disabling such Stockholder from performing its obligations
under this Agreement or making any representation or warranty of such contained
in this Agreement untrue or incorrect; or (d) enter into any agreement or
arrangement providing for any of the actions described in clause (a), (b) or (c)
above.
Termination. The Voting Agreement terminates upon the earliest to occur
of (i) the Merger Effective Time, (ii) the valid termination of the Merger
Agreement in accordance with its terms, (iii) the execution of any amendment to
the Merger Agreement that modifies the amount, form or timing of payment of the
Merger Consideration in a manner adverse to any Stockholder without the prior
written consent of such Stockholder or (iv) the mutual agreement of the parties
hereto.
Certain Events. OrbiMed Advisors LLC agrees that the Voting Agreement
and its obligations thereunder shall attach to its Subject Shares and shall be
binding upon any person or entity to which legal or beneficial ownership of such
Subject Shares shall pass, whether by operation of law or otherwise, including,
without limitation, OrbiMed Advisors LLC's successors. Notwithstanding any
transfer of Subject Shares, the transferor shall remain liable for the
performance of all its obligations under the Voting Agreement.
The preceding summary of certain provisions of the Voting Agreement is
not intended to be complete and is qualified in its entirety by reference to the
full text of the Voting Agreement and the Merger Agreement, copies of which are
filed as exhibits hereto and are incorporated herein by reference.
Except as set forth above, the Reporting Persons have not formulated
any plans or proposals which relate to or would result in: (a) the acquisition
by any person of additional
Page 9 of 15
securities of the Issuer or the disposition of securities of the Issuer, (b) an
extraordinary corporate transaction involving the Issuer or any of its
subsidiaries, (c) a sale or transfer of a material amount of the assets of the
Issuer or any of its subsidiaries, (d) any change in the present board of
directors or management of the Issuer, (e) any material change in the Issuer's
capitalization or dividend policy, (f) any other material change in the Issuer's
business or corporate structure, (g) any change in the Issuer's charter or
bylaws or other or instrument corresponding thereto or other action which may
impede the acquisition of control of the Issuer by any person, (h) causing a
class of the Issuer's securities to be deregistered or delisted, (i) a class of
equity securities of the Issuer becoming eligible for termination of
registration or (j) any action similar to any of those enumerated above.
Item 5. Interest in Securities of the Issuer.
(a)-(b) As of the date of this filing, OrbiMed Advisors LLC, OrbiMed
Capital LLC, and Samuel D. Isaly may be deemed directly or indirectly, including
by reason of their mutual affiliation, to be the beneficial owners of the Common
Stock described in Item 3. Based upon information contained in the most recent
available filing by the Issuer with the SEC, such Shares constitute
approximately 14.16% of the issued and outstanding Shares. As described above in
Item 2, Isaly owns, pursuant to the terms of the limited liability company
agreement of OrbiMed Advisors LLC and OrbiMed Capital LLC, a controlling
interest in the outstanding limited liability company interests of such entity.
As a result, Isaly and OrbiMed Advisors LLC and OrbiMed Capital LLC share power
to direct the vote and to direct the disposition of the Common Stock described
in Item 3.
(c) No transactions with respect to the Shares were effected during the
past sixty (60) days by any of the Reporting Persons.
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer.
Other than the agreements and the relationships mentioned above, to the
best knowledge of the Reporting Persons, there are no contracts, arrangements,
understandings or relationships (legal or otherwise) among the persons named in
Item 2 and between such persons and any persons with respect to any securities
of the Issuer, including, but not limited to, transfer or voting of any of the
Shares, finder's fees, joint ventures, loan or option arrangements, puts or
calls, guarantees of profits, division of profits or loss, or the giving of
withholding of proxies.
Item 7. Materials to be Filed as Exhibits.
Exhibit Description
A. Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed
Capital LLC, and Samuel D. Isaly.
B. Merger Agreement and Plan of Merger, dated April 18, 2005,
among Orphan Medical
Page 10 of 15
Inc., Jazz Pharmaceuticals, Inc., and Twist Merger Sub, Inc.
(incorporated by reference to Exhibit 2.1 to the Current Report
on Form 8-K of Orphan Medical Inc. filed April 20, 2005).
C. Voting Agreement, dated April 18, 2005, among Orphan Medical
Inc., Jazz Pharmaceuticals, Inc., Twist Merger Sub, Inc.,
OrbiMed Advisors LLC and each stockholder of the Company
signatory thereto (incorporated by reference to Exhibit 10.1
filed with the Current Report on Form 8-K of Orphan Medical Inc.
filed on April 20, 2005).
Page 11 of 15
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: May 5, 2005
OrbiMed Advisors LLC
By: /s/ Samuel D. Isaly
---------------------------
Name: Samuel D. Isaly
Title: Managing Partner
OrbiMed Capital LLC
By: /s/ Samuel D. Isaly
----------------------------
Name: Samuel D. Isaly
Title: Managing Partner
By: /s/ Samuel D. Isaly
----------------------------
Name: Samuel D. Isaly
Page 12 of 15
Schedule I
The name and present principal occupation of each of the executive
officers and directors of OrbiMed Advisors LLC are set forth below. Unless
otherwise noted, each of these persons are United States citizens and have as
their business address 767 Third Avenue, New York, NY 10017.
=================================================================================================================
Position with Reporting
Name Person Principal Occupation
-----------------------------------------------------------------------------------------------------------------
Samuel D. Isaly Managing Partner Partner
OrbiMed Advisors LLC
-----------------------------------------------------------------------------------------------------------------
Michael Sheffery Partner Partner
OrbiMed Advisors LLC
-----------------------------------------------------------------------------------------------------------------
Carl L. Gordon Partner Partner
OrbiMed Advisors LLC
-----------------------------------------------------------------------------------------------------------------
Sven Borho Partner Partner
German and Swedish Citizen OrbiMed Advisors LLC
-----------------------------------------------------------------------------------------------------------------
Jonathan T. Silverstein Partner Partner
OrbiMed Advisors LLC
-----------------------------------------------------------------------------------------------------------------
Eric A. Bittelman Chief Financial Officer and CFO/CCO
Chief Compliance Officer OrbiMed Advisors LLC
=================================================================================================================
Page 13 of 15
Schedule II
The name and present principal occupation of each of the executive
officers and directors of OrbiMed Capital LLC are set forth below. Unless
otherwise noted, each of these persons are United States citizens and have as
their business address 767 Third Avenue, New York, NY 10017.
=================================================================================================================
Position with Reporting
Name Person Principal Occupation
-----------------------------------------------------------------------------------------------------------------
Samuel D. Isaly Managing Partner Partner
OrbiMed Capital LLC
-----------------------------------------------------------------------------------------------------------------
Michael Sheffery Partner Partner
OrbiMed Capital LLC
-----------------------------------------------------------------------------------------------------------------
Carl L. Gordon Partner Partner
OrbiMed Capital LLC
-----------------------------------------------------------------------------------------------------------------
Sven Borho Partner Partner
German and Swedish Citizen OrbiMed Capital LLC
-----------------------------------------------------------------------------------------------------------------
Jonathan T. Silverstein Partner Partner
OrbiMed Capital LLC
-----------------------------------------------------------------------------------------------------------------
Eric A. Bittelman Chief Financial Officer and Chief CFO/CCO
Compliance Officer OrbiMed Capital LLC
=================================================================================================================
Page 14 of 15
EXHIBIT INDEX
--------------------------------------------------------------------------------
Exhibit Description Page No.
--------------------------------------------------------------------------------
A. Joint Filing Agreement among OrbiMed A-1
Advisors LLC, OrbiMed Capital LLC, and
Samuel D. Isaly.
--------------------------------------------------------------------------------
Page 15 of 15
Exhibit A.
JOINT FILING AGREEMENT
The undersigned hereby agree that the Statement on this Schedule 13D,
dated April 18, 2005 (the "Schedule 13D"), with respect to the Common Stock, par
value $.01 per share, of Orphan Medical Inc. is filed on behalf of each of us
pursuant to and in accordance with the provisions of Rule 13d-1(k) under the
Securities and Exchange Act of 1934, as amended, and that this Agreement shall
be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees
to be responsible for the timely filing of the Schedule 13D, and for the
completeness and accuracy of the information concerning itself contained
therein. This Agreement may be executed in any number of counterparts, all of
which taken together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of
the 5th day of May 2005.
OrbiMed Advisors LLC
By: /s/ Samuel D. Isaly
---------------------------
Name: Samuel D. Isaly
Title: Managing Partner
OrbiMed Capital LLC
By: /s/ Samuel D. Isaly
----------------------------
Name: Samuel D. Isaly
Title: Managing Partner
By: /s/ Samuel D. Isaly
----------------------------
Name: Samuel D. Isaly
A-1